SAGAsafe® (formerly known as IBSAFE) is based on digital PCR (dPCR) and detects and quantifies mutations with unique ultrasensitivity to 0.001% MAF (Mutant Allele Frequency). This is approximately 100-fold improved compared to competing methods.
SAGA has developed and validated more than 250 different assays to date, covering most of the mutations of clinical interest*.
SAGAsign® (formerly known as KROMA) is a unique hybrid method which is ideal for monitoring of response to therapy, MRD (minimal residual disease), and recurrences. The predictive power of SAGAsign® has been verified in clinical studies*. We have been able to predict recurrences in breast cancer patients and identify metastatic disease up to 3-years prior to patient symptoms.
SAGAseq® is a third platform technology currently in development which marries enhanced sequencing library preparation together with AI/machine learning bioinformatics to reduce sequencing noise and increase true-positive signal. Pan-cancer, tumor-type-specific, TMB (tumor mutational burden), and other customizable panels will be available.